Belvedere Trading
AMAM

Belvedere Trading’s Ambrx Biopharma Inc AMAM Stock Holding History

Belvedere Trading’s Portfolio AMAM Stock Details AMAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-29,500
Closed -$339K – 1053
2023
Q3 		$339K Buy
29,500
+9,800
+50% +$133K ﹤0.01% 151
2023
Q2 		$324K Buy
19,700
+4,500
+30% +$56.6K ﹤0.01% 207
2023
Q1 		$136K Buy
+15,200
New +$76.4K ﹤0.01% 409

Other funds holding AMAM

DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Belvedere Trading's AMAM Position: Q3 2023 in Review

Belvedere Trading sold out of Ambrx Biopharma Inc (AMAM) in Q3 2023, closing a stake of 13,872 shares — an estimated $189K sold.

Belvedere Trading first reported a position in AMAM in Q1 2023 and held it in 2 quarters. The position peaked at $228K in Q2 2023. 44 funds tracked by Wall St. Rank hold AMAM as of Q3 2023.

  • Belvedere Trading reported no remaining Ambrx Biopharma Inc position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 13,872 Ambrx Biopharma Inc shares in Q3 2023, an estimated $189K.
  • Belvedere Trading first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 2 quarters.
  • Belvedere Trading's Ambrx Biopharma Inc position peaked at $228K in Q2 2023.
  • 44 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.